Study-related adverse events The adverse events most commonly reported in 5% of adult patients treated with Victoza 1.8 mg vs Januvia 100 mg, both in combination with metformin, were nausea (21.8% vs 7.8%), diarrhea (16.3% vs 9.3%), decreased appetite (8.9% vs 3.4%), vomiting (7.4% vs 4.9%), headache (6.4% vs 5.9%), nasopharyngitis (5.9% vs 3.4%), and increased lipase (5.5% vs 4.4%)
Methylation of R21 promotes the polyubiquitination and degradation of MRPS23, which inhibits mitochondrial phosphorylation (OXPHOS) and increases ROS levels, thereby promoting breast cancer cell metastasis
Pregnant women or those planning pregnancy should delay therapy and discuss timing with their provider
Dietary intake of fish, n-3 polyunsaturated fatty acids, and risk of inflammatory bowel disease: a systematic review and meta-analysis of observational studies